Positron Emission Tomography
Positron Emission Tomography Market Forecasts to 2030 - Global Analysis By Product (Radiotracers, Positron Emission Tomography (PET) Scanners, Radiopharmaceuticals and Other Products), Application, End User and By Geography
Years Covered |
2021-2030 |
Estimated Year Value (2023) |
US $1.5 BN |
Projected Year Value (2030) |
US $2.7 BN |
CAGR (2023 - 2030) |
8.6% |
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
Largest Market |
Asia Pacific |
Highest Growing Market |
North America |
According to Stratistics MRC, the Global Positron Emission Tomography Market is accounted for $1.5 billion in 2023 and is expected to reach $2.7 billion by 2030 growing at a CAGR of 8.6% during the forecast period. A nuclear medicine and biochemical analysis technique called ""positron emission tomography"" (PET) is used to measure the metabolic activity of cells. Through an intravenous (IV) line, a small quantity of radioactive glucose, or sugar, is injected into the patient's vein. PET scans are mostly utilized in oncology, where they help with cancer identification, staging, and therapy monitoring by allowing the imaging and assessment of metabolic activity in tissues. PET scans help physicians identify problems and evaluate the effectiveness of treatment by providing precise images of physiological processes at the molecular level through the use of radioactive tracers.
According to the World Nuclear Association April 2022 update, around 40 million nuclear medicine procedures are performed each year, and demand for radioisotopes is increasing by up to 5% annually.
Market Dynamics:
Driver:
Rising incidence of cancer
The need for sophisticated diagnostic instruments has increased as cancer incidence is rising, especially in elderly people. PET imaging is vital to oncology because of its popularity for identifying molecular-level metabolic activity. By offering extensive knowledge of the metabolic processes of tissues, it facilitates accurate cancer diagnosis, staging, and therapy response monitoring. Moreover, PET scans are a vital tool that oncologists can use to adapt therapies depending on the needs of each patient as healthcare systems throughout the world grapple with the rising incidence of cancer.
Restraint:
High capital cost
PET scanners have become costly for many healthcare facilities, especially those with limited resources, due to the significant financial outlays required for their purchase, setup, and maintenance. This high capital cost is a result of the sophisticated technology and particular components needed for PET imaging, which restricts the availability of PET scans for patients and healthcare providers. However, the cost burden extends beyond the original purchase and includes continuing expenditures for radiopharmaceutical supply, equipment maintenance, and qualified worker training.
Opportunity:
Growing emphasis on personalized medicine
PET is essential to the paradigm shift in medical care, which is shifting more and more toward customized and tailored therapies. PET imaging offers vital information on the distinct molecular features of diseases, enabling an improved understanding of how each patient will respond to treatment. PET helps doctors identify the most effective treatments and track their effects by allowing them to witness metabolic activity at the molecular level. In addition to improving diagnostic precision, this individualized approach helps develop more focused and effective therapies that minimize adverse effects and maximize outcomes for patients.
Threat:
Limited accessibility of cyclotrons
Short-lived radioisotopes, like fluorine-18, are generated in cyclotrons and are crucial for PET imaging. However, cyclotron accessibility and availability are frequently limited, especially in certain geographical areas or medical facilities. The installation and operation of cyclotrons require expensive and sophisticated infrastructure, which makes it difficult to establish PET imaging centers in places where these resources are limited. In addition to impeding the further integration of PET technology, this restriction on cyclotron accessibility creates logistical difficulties in ensuring an ongoing supply of radiopharmaceuticals.
Covid-19 Impact:
Healthcare services were disrupted as a result of the epidemic, and controlling and restricting the virus gained precedence. Several non-urgent medical procedures—such as certain diagnostic imaging studies—were canceled or postponed in order to use resources more effectively for pandemic-related initiatives. This resulted in a brief decrease in demand for the routine use of PET scans for a variety of medical disorders. PET imaging services' accessibility was further limited by supply chain problems, logistical difficulties, and patient mobility limitations. Healthcare systems faced difficulties adhering to regular maintenance schedules and delays in the installation of new PET equipment as they adjusted to the changing pandemic environment.
The radiotracers segment is expected to be the largest during the forecast period
Radiotracers segment is expected to be the largest during the forecast period. Short-lived radioactive chemicals, or radiotracers, are essential parts of PET imaging that make the body's metabolic activities accessible. The growing need for a variety of specific radiotracers is a result of the growing uses of PET in oncology, cardiology, and neurology, among other medical specialties. Moreover, novel tracers have been developed as a result of developments in radiopharmaceutical research and development, improving diagnostic precision and broadening the application of PET imaging.
The cardiology segment is expected to have the highest CAGR during the forecast period
Cardiology segment is expected to have the highest CAGR. PET imaging is becoming more and more popular in cardiology due to its incredible ability to offer high-resolution, functional insights into heart metabolism and blood flow. When it comes to the detection and treatment of cardiovascular diseases, including myocardial infarction and coronary artery disease, this technology is essential. Moreover, because PET may provide comprehensive information about heart function, viability, and perfusion, it is highly sought after in cardiology. This information helps doctors make timely and precise decisions regarding patient care.
Region with largest share:
Asia Pacific region dominated the largest share. PET imaging use is being aided by the region's expanding healthcare infrastructure and rising medical technology investments. Growing rates of chronic illnesses, such as cancer and heart problems, are driving up the need for sophisticated diagnostic instruments, of which PET is an essential component. Governments around Asia-Pacific are promoting the incorporation of cutting-edge imaging technologies as a means of enhancing healthcare quality and accessibility.
Region with highest CAGR:
Due to factors including the growing need for precision diagnostics and the technological improvements in PET imaging for oncology and advanced diagnostic applications, the North American region is projected to have lucrative growth. Significant market growth in the region is also anticipated due to the increasing incidence of cancer cases, including prostate and breast cancer. For instance, according to the American Cancer Society's 2022 forecast, 1,918,030 new cases of cancer are expected in the United States in 2022.
Key players in the market
Some of the key players in Positron Emission Tomography market include GE Healthcare, Philips Healthcare, Toshiba Corporation, Hitachi, Ltd, Rigaku Corporation, Siemens Healthineers, Positron Corporation, Medtronic plc, PerkinElmer, Inc., Eckert & Ziegler Group, Naviscan, Inc., Cubresa Inc, Raycan Technology Co., Ltd, CMR Naviscan Corporation, Navidea Biopharmaceuticals and Rotem Industries Ltd.
Key Developments:
In August 2022, Positron Corporation, a nuclear medicine PET imaging device system and clinical services company, purchased its first PET-CT system and was on its way from its partner Neusoft Medical Systems. Positron's ""Affinity PET-CT"" system is on its way from China to its validation partner in the United States.
In July 2022, Radialis Inc. received clearance to market the Radialis PET Imager, an organ-targeted positron emission tomography (PET) system, in the United States. The advanced sensitivity of the Radialis PET Imager to radiotracer enables the system to produce functional images with high spatial resolution, expanding the insight available from molecular imaging.
Products Covered:
• Radiotracers
• Positron Emission Tomography (PET) Scanners
• Radiopharmaceuticals
• Other Products
Applications Covered:
• Neurology
• Cardiology
• Infectious Diseases
• Oncology
• Pulmonary Disorders
• Research and Drug Development
• Other Applications
End Users Covered:
• Specialty Clinics
• Cancer Treatment Centers
• Diagnostic Centers
• Hospitals
• Radiology Centers
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Positron Emission Tomography Market, By Product
5.1 Introduction
5.2 Radiotracers
5.3 Positron Emission Tomography (PET) Scanners
5.4 Radiopharmaceuticals
5.5 Other Products
6 Global Positron Emission Tomography Market, By Application
6.1 Introduction
6.2 Neurology
6.2.1 Alzheimer's Disease and Dementia
6.2.2 Brain Tumor Evaluation
6.2.3 Psychiatric Disorders
6.2.4 Movement Disorders
6.2.5 Neuroreceptor Imaging
6.3 Cardiology
6.3.1 Coronary Artery Disease Evaluation
6.3.2 Inflammation Imaging
6.3.3 Myocardial Perfusion Imaging
6.3.4 Atherosclerosis Imaging
6.3.5 Endocarditis Evaluation
6.4 Infectious Diseases
6.5 Oncology
6.6 Pulmonary Disorders
6.7 Research and Drug Development
6.8 Other Applications
7 Global Positron Emission Tomography Market, By End User
7.1 Introduction
7.2 Specialty Clinics
7.3 Cancer Treatment Centers
7.4 Diagnostic Centers
7.5 Hospitals
7.6 Radiology Centers
7.7 Other End Users
8 Global Positron Emission Tomography Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa
9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies
10 Company Profiling
10.1 GE Healthcare
10.2 Philips Healthcare
10.3 Toshiba Corporation
10.4 Hitachi, Ltd
10.5 Rigaku Corporation
10.6 Siemens Healthineers
10.7 Positron Corporation
10.8 Medtronic plc
10.9 PerkinElmer, Inc.
10.10 Eckert & Ziegler Group
10.11 Naviscan, Inc.
10.12 Cubresa Inc
10.13 Raycan Technology Co., Ltd
10.14 CMR Naviscan Corporation
10.15 Navidea Biopharmaceuticals
10.16 Rotem Industries Ltd
List of Tables
1 Global Positron Emission Tomography Market Outlook, By Region (2021-2030) ($MN)
2 Global Positron Emission Tomography Market Outlook, By Product (2021-2030) ($MN)
3 Global Positron Emission Tomography Market Outlook, By Radiotracers (2021-2030) ($MN)
4 Global Positron Emission Tomography Market Outlook, By Positron Emission Tomography (PET) Scanners (2021-2030) ($MN)
5 Global Positron Emission Tomography Market Outlook, By Radiopharmaceuticals (2021-2030) ($MN)
6 Global Positron Emission Tomography Market Outlook, By Other Products (2021-2030) ($MN)
7 Global Positron Emission Tomography Market Outlook, By Application (2021-2030) ($MN)
8 Global Positron Emission Tomography Market Outlook, By Neurology (2021-2030) ($MN)
9 Global Positron Emission Tomography Market Outlook, By Alzheimer's Disease and Dementia (2021-2030) ($MN)
10 Global Positron Emission Tomography Market Outlook, By Brain Tumor Evaluation (2021-2030) ($MN)
11 Global Positron Emission Tomography Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
12 Global Positron Emission Tomography Market Outlook, By Movement Disorders (2021-2030) ($MN)
13 Global Positron Emission Tomography Market Outlook, By Neuroreceptor Imaging (2021-2030) ($MN)
14 Global Positron Emission Tomography Market Outlook, By Cardiology (2021-2030) ($MN)
15 Global Positron Emission Tomography Market Outlook, By Coronary Artery Disease Evaluation (2021-2030) ($MN)
16 Global Positron Emission Tomography Market Outlook, By Inflammation Imaging (2021-2030) ($MN)
17 Global Positron Emission Tomography Market Outlook, By Myocardial Perfusion Imaging (2021-2030) ($MN)
18 Global Positron Emission Tomography Market Outlook, By Atherosclerosis Imaging (2021-2030) ($MN)
19 Global Positron Emission Tomography Market Outlook, By Endocarditis Evaluation (2021-2030) ($MN)
20 Global Positron Emission Tomography Market Outlook, By Infectious Diseases (2021-2030) ($MN)
21 Global Positron Emission Tomography Market Outlook, By Oncology (2021-2030) ($MN)
22 Global Positron Emission Tomography Market Outlook, By Pulmonary Disorders (2021-2030) ($MN)
23 Global Positron Emission Tomography Market Outlook, By Research and Drug Development (2021-2030) ($MN)
24 Global Positron Emission Tomography Market Outlook, By Other Applications (2021-2030) ($MN)
25 Global Positron Emission Tomography Market Outlook, By End User (2021-2030) ($MN)
26 Global Positron Emission Tomography Market Outlook, By Specialty Clinics (2021-2030) ($MN)
27 Global Positron Emission Tomography Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
28 Global Positron Emission Tomography Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
29 Global Positron Emission Tomography Market Outlook, By Hospitals (2021-2030) ($MN)
30 Global Positron Emission Tomography Market Outlook, By Radiology Centers (2021-2030) ($MN)
31 Global Positron Emission Tomography Market Outlook, By Other End Users (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.